To diagnose Alzheimer’s disease, neuroimaging techniques (MRI, PET) may be used to determine certain biomarkers. However, this data remains incomplete.
This has prompted an international team, steered by Professor Giovanni Frisoni, director of HUG’s memory centre (FR), to adapt the approach used for cancer to Alzheimer’s disease.
The results of this research were published in Lancet Neurology in 2017. They represent a first step to detecting early diseases better, developing diagnostic algorithms and formulating directives to regulate the use of these biomarkers.